CYPH

Liquidity: As of December 31, 2024, the company held $47.2 million in cash and cash equivalents. Management believes this is sufficient to fund operations for at least 12 months from the filing date.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately $13.9 million (17%) compared to 2023. This improvement was primarily driven by a $29.6 million non-cash expense in 2023 related to in-process research and development (IPR&D) acquired from the Flame Biosciences merger, which was not present in 2024.
• R&D Expenses: Total R&D expenses decreased by $16.0 million. While clinical trial costs increased due to the expansion of the DeFianCe study and the DisTinGuish study, these increases were offset by the absence of the 2023 IPR&D write-off.
• Financing Activity: In April 2024, the company completed a private placement raising approximately $40.0 million in gross proceeds (net of $2.9 million in offering costs). In 2023, financing activities were minimal.
• Strategic Pivot: Following negative primary endpoints in the DisTinGuish Part C study for gastric cancer, the company decided not to pursue Phase 3 development in that indication and redirected resources to its colorectal cancer program.

Guidance, Outlook, Risks, and Unusual Items

Clinical Outlook and Guidance

• DeFianCe Study (Colorectal Cancer): Preliminary data from the randomized Part B of the DeFianCe study showed improved Overall Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS) in the experimental arm compared to control, particularly in patients with high circulating DKK1 levels and those without prior anti-VEGF therapy.
• DisTinGuish Study (Gastric Cancer): The study failed to meet its primary PFS endpoint. The company will not advance this program to Phase 3.
• Capital Needs: The company expects to continue incurring significant operating losses. It will require additional capital to fund future operations, likely through equity financings, debt, or strategic collaborations.

Risks and Contingencies

• Nasdaq Listing Compliance: On March 12, 2025, the company received notice from Nasdaq regarding non-compliance with the $1.00 minimum closing bid price rule. The company has an initial 180-day period (until September 8, 2025) to regain compliance, potentially via a reverse stock split.
• Going Concern: While the company has a 12-month cash runway, it has an accumulated deficit of $467.4 million and no product revenue. Continued losses and the need for additional financing pose significant risks.
• Intellectual Property: The company relies on licensed patents from Eli Lilly and its own portfolio. Patent expirations range from 2030 to 2045 depending on the specific family and jurisdiction.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $47.2 million cash balance against current burn rates and the timeline for the next financing round.
• Nasdaq Compliance: Monitor the company's progress in regaining compliance with the $1.00 minimum bid price requirement to avoid delisting.
• Clinical Data Maturation: Confirm the final, audited results of the DeFianCe study, particularly the statistical significance of the PFS and OS data in the high DKK1 population.
• Regulatory Strategy: Assess the company's plan for regulatory submission for sirexatamab in colorectal cancer following the strategic pivot away from gastric cancer.
• Warrant Dilution: Review the impact of outstanding warrants (including pre-funded warrants exercised in Q1 2025) on potential future dilution.